Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans
研究概览
详细说明
Avid has previously developed a florbetapir-PET scan binary read methodology and training program, which was successfully applied in studies 18F-AV-45-A08(NCT01565369), 18F-AV-45-A09(NCT01565382) and 18F-AV-45-A16(NCT01447719). In these previous studies, training was conducted in-person. Study 18F-AV-45-PT01 will evaluate an automated version of this training program suitable for web-based distribution. Nuclear medicine physicians will complete the automated training program then read the florbetapir-PET images from 151 subjects with repeat readings of 33 randomly selected images. Readers will rate each case as either positive for significant tracer accumulation in cortical gray matter or negative for significant tracer accumulation in cortical gray matter. The inter-rater reliability, sensitivity and specificity of the readers will be evaluated.
The primary image set for determination of inter-reader agreement is comprised of images from 119 subjects from two previous clinical studies (A07[NCT00857415]/A16[NCT01447719] and A05[NCT00702143]). This included all 59 subjects who came to autopsy in Study A07(NCT00857415) and it's follow-up study, A16(NCT01447719), and a set of 60 cases randomly selected from Study A05(NCT00702143) subjects, including 20 cognitively-normal controls, 20 with mild cognitive impairment) MCI, 20 with AD.
Subsequently, the protocol was amended to include all remaining A05(NCT00702143) MCI patients that were not used in the training program (n=32); 13 of these 32 scans presented for repeat reading (to increase the number of A05 MCI cases with repeated reads to 20). This increased the number of unique cases in the validation dataset to 151 scans with 33 scans repeated yielding a total of 184 scans reviewed by the readers.
研究类型
注册 (实际的)
阶段
- 不适用
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Eligibility for subjects scans to be used in this study is determined by subject's eligibility/enrollment in Study A05 (NCT00702143) or A07 (NCT00857415).
Alzheimer's disease (AD) group key eligibility criteria (from Study A05[NCT00702143]):
- Male or female at least 50 years of age
- Have probable AD per National Institute of Neurological and Communication Disorders and Stroke (NINCDS) criteria
- Mini mental state exam (MMSE) score between 10 and 24 inclusive
Mild cognitive impairment group key eligibility criteria (from Study A05[NCT00702143):
- Male or female at least 50 years of age
- Complaints of memory or cognitive decline corroborated by an informant
- Clinical dementia rating of 0.5
- No obvious cause for cognitive impairment (eg, head trauma or stroke)
- Cognitive impairment onset within the past year
- MMSE score greater than 24
Cognitively normal volunteer group key eligibility criteria (from Study A05[NCT00702143]):
- Male or female at least 50 years of age
- MMSE score greater than or equal to 29 and cognitively normal by informant report and psychometric test battery at screening
Autopsy cohort key eligibility criteria (from Study A07[NCT00857415]):
- Male or female 18 years or older
- Projected life expectancy of less than 6 months
- Consent to brain donation
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:单身的
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Inter-rater Reliability
大体时间:Scan acquired 50-60 min post-injection
|
Measure of agreement among five readers using a binary read method (amyloid positive/negative) calculated using Fleiss' kappa.
All scans were read in a blinded fashion without access to clinical information.
|
Scan acquired 50-60 min post-injection
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Sensitivity of Florbetapir-PET to Detect Moderate to Frequent Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)
大体时间:at autopsy, within 2 years of scan
|
Calculated as the percent of true positives which are correctly identified
|
at autopsy, within 2 years of scan
|
|
Specificity of Florbetapir-PET to Detect no or Sparse Beta-amyloid Neuritic Plaques (Probable/Definite Alzheimer's Disease)
大体时间:at autopsy, within 2 years of scan
|
Calculated as the percent of true negatives which are correctly identified
|
at autopsy, within 2 years of scan
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Median Sensitivity and Specificity vs. CERAD Diagnosis
大体时间:Baseline scan
|
Median sensitivity and specificity for 5 independent readers to detect moderate to frequent amyloid plaques (per CERAD criteria).
|
Baseline scan
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.